Tenax Therapeutics with ticker code (TENX) now have 2 analysts covering the stock. The analyst consensus points to a rating of ‘None’. The range between the high target price and low target price is between 4 and 2 calculating the average target price we see 3. With the stocks previous close at 1.03 this indicates there is a potential upside of 191.3%. The 50 day moving average now sits at 1.05 while the 200 day moving average is 1.21. The market capitalisation for the company is $14m. Visit the company website at: http://www.tenaxthera.com
Tenax Therapeutics, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome. It is also involved in initiating a Phase 2 clinical trial of levosimendan for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction. The company was formerly known as Oxygen Biotherapeutics and changed its name to Tenax Therapeutics in September 2014. Tenax Therapeutics was founded in 1967 and is headquartered in Morrisville, North Carolina.